

Product sales

Full year 2025 product sales

The following table provides the top 20 product net sales from continuing operations in 2025, as well as the change compared with 2024:

Brands	Net Sales (USD m)	% change (USD)	% change (cc ¹)	Brand classification by therapeutic area or established brands
<i>Entresto</i>	7,748	-1	-2	Cardiovascular, renal and metabolic
<i>Cosentyx</i>	6,668	9	8	Immunology
<i>Kisqali</i>	4,783	58	57	Oncology
<i>Kesimpta</i>	4,426	37	36	Neuroscience
<i>Tafinlar + Mekinist</i>	2,215	8	6	Oncology
<i>Jakavi</i>	2,110	9	7	Oncology
<i>Pluvicto</i>	1,994	43	42	Oncology
<i>Ilaris</i>	1,883	25	24	Immunology
<i>Xolair</i> ²	1,723	5	4	Immunology
<i>Promacta/Revolade</i>	1,636	-26	-27	Oncology
<i>Scemblix</i>	1,285	87	85	Oncology
<i>Zolgensma</i> Group	1,232	1	0	Neuroscience
<i>Sandostatin</i> Group	1,213	-5	-5	Established brands
<i>Leqvio</i>	1,198	59	57	Cardiovascular, renal and metabolic
<i>Tasigna</i>	1,104	-34	-34	Oncology
<i>Lutathera</i>	816	13	12	Oncology
<i>Exforge</i> Group	727	3	4	Established brands
<i>Lucentis</i>	643	-38	-40	Established brands
<i>Diovan</i> Group	604	2	2	Established brands
<i>Fabhalta</i> ³	505	291	287	Oncology

1. For an explanation of non-IFRS measures and reconciliation tables, see the Annual Report 2025: “—Non-IFRS measures as defined by Novartis.”
2. Net sales from continuing operations reflect *Xolair* sales for all indications.
3. Net sales from continuing operations reflect *Fabhalta* sales for all indications.

Source URL: <https://www.novartis.com/investors/financial-data/product-sales>

List of links present in page

1. <https://www.novartis.com/investors/financial-data/product-sales>